JNJ-18038683

From WikiMD's Wellness Encyclopedia

JNJ-18038683 is a drug that was developed by Johnson & Johnson for the potential treatment of cognitive disorders, insomnia, and depression. It acts as a selective 5-HT2A receptor antagonist and 5-HT2C receptor inverse agonist, and has been shown to enhance cognition in animal studies.

Pharmacology[edit | edit source]

JNJ-18038683 is a serotonin antagonist and inverse agonist at the 5-HT2A and 5-HT2C receptors. These receptors are part of the serotonin system, which plays a key role in regulating mood, cognition, and sleep. By blocking the activity of these receptors, JNJ-18038683 may help to improve symptoms in conditions such as cognitive disorders, insomnia, and depression.

Clinical trials[edit | edit source]

JNJ-18038683 has undergone Phase I clinical trials for the treatment of cognitive disorders, insomnia, and depression. However, the results of these trials have not been publicly disclosed, and it is unclear whether the drug will proceed to Phase II clinical trials.

See also[edit | edit source]

References[edit | edit source]


JNJ-18038683 Resources
Wikipedia
WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD